TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice-Reference-Cited by-同舟云学术

TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits γ-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice

Published:2020-06 Issue:8 Volume:158 Page:2266-2281.e27
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Zhao Mingming,Zhao Lin,Xiong Xuelian,He Yuan,Huang Wei,Liu Zihao,Ji Liang,Pan Bing,Guo Xuefeng,Wang Leibo,Cheng Si^ORCID,Xu Ming,Yang Hongyuan^ORCID,Yin Yuxin,Garcia-Barrio Minerva T.,Chen Y. Eugene,Meng Xiangbao,Zheng Lemin

Funder

Fundamental Research Funds for the Central Universities

National Natural Science Foundation of China

Ministry of Science and Technology of the People's Republic of China

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference56 articles.

1. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis;Diehl;N Engl J Med,2017

2. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice;Kim;J Biol Chem,2000

3. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial;Zhang;JAMA Intern Med,2016